Table 2. Characteristics of the Patients According to SARS-CoV-2 Test Results and Vaccination Status.*.
| Characteristic | All Visits | Assay for SARS-CoV-2 | Standardized Mean Difference† | Vaccination Status‡ | Standardized Mean Difference§ | |||||
|---|---|---|---|---|---|---|---|---|---|---|
| Negative | Positive | Unvaccinated | Partial, 1 Dose of mRNA Vaccine | Partial, 2 Doses of mRNA Vaccine | Full, 2 Doses of mRNA Vaccine |
Full, Ad26.COV2.S Vaccine |
||||
| number (percent of all visits) | number (percent of all visits) | |||||||||
| Hospitalization | ||||||||||
| All hospitalizations | 41,552 (100) | 37,231 (90) | 4321 (10) | −0.13 | 20,406 (49) | 3083 (7) | 2482 (6) | 14,874 (36) | 707 (2) | 0.05 |
| First | 40,367 (97) | 36,096 (89) | 4271 (11) | 19,903 (49) | 3003 (7) | 2456 (6) | 14,361 (36) | 644 (2) | ||
| Repeat | 1,185 (3) | 1,135 (96) | 50 (4) | 503 (42) | 80 (7) | 26 (2) | 513 (43) | 63 (5) | ||
| Partner | 0.56 | 0.78 | ||||||||
| CUIMC | 3,126 (8) | 2,458 (79) | 668 (21) | 2,181 (70) | 216 (7) | 103 (3) | 588 (19) | 38 (1) | ||
| HealthPartners | 989 (2) | 928 (94) | 61 (6) | 389 (39) | 98 (10) | 104 (11) | 390 (39) | 8 (1) | ||
| Intermountain Healthcare | 3,910 (9) | 3,353 (86) | 557 (14) | 1,917 (49) | 392 (10) | 278 (7) | 1,236 (32) | 87 (2) | ||
| KPNC | 13,824 (33) | 13,159 (95) | 665 (5) | 3,559 (26) | 1021 (7) | 980 (7) | 7,874 (57) | 390 (3) | ||
| KPNW | 1,952 (5) | 1,834 (94) | 118 (6) | 906 (46) | 210 (11) | 132 (7) | 651 (33) | 53 (3) | ||
| Regenstrief Institute | 12,437 (30) | 10,776 (87) | 1661 (13) | 7,593 (61) | 925 (7) | 674 (5) | 3,114 (25) | 131 (1) | ||
| University of Colorado | 5,314 (13) | 4,723 (89) | 591 (11) | 3,861 (73) | 221 (4) | 211 (4) | 1,021 (19) | 0 | ||
| Age group | 0.26 | 0.34 | ||||||||
| 50–64 yr | 8,764 (21) | 7,436 (85) | 1328 (15) | 5,532 (63) | 585 (7) | 467 (5) | 1,898 (22) | 282 (3) | ||
| 65–74 yr | 13,158 (32) | 11,839 (90) | 1319 (10) | 6,681 (51) | 1014 (8) | 795 (6) | 4,481 (34) | 187 (1) | ||
| 75–84 yr | 12,282 (30) | 11,193 (91) | 1089 (9) | 5,233 (43) | 935 (8) | 772 (6) | 5,189 (42) | 153 (1) | ||
| ≥85 yr | 7,348 (18) | 6,763 (92) | 585 (8) | 2,960 (40) | 549 (7) | 448 (6) | 3,306 (45) | 85 (1) | ||
| ICU admission | 0.01 | −0.10 | ||||||||
| Yes | 7,394 (18) | 6,606 (89) | 788 (11) | 4,024 (54) | 512 (7) | 388 (5) | 2,359 (32) | 111 (2) | ||
| No | 34,158 (82) | 30,625 (90) | 3533 (10) | 16,382 (48) | 2571 (8) | 2094 (6) | 12,515 (37) | 596 (2) | ||
| Covid-19 vaccine | 0.95 | NA | ||||||||
| Unvaccinated | 20,406 (49) | 16,711 (82) | 3695 (18) | 20,406 (100) | ||||||
| BNT162b2 | 11,292 (27) | 10,932 (97) | 360 (3) | 1444 (13) | 1348 (12) | 8,500 (75) | ||||
| mRNA-1273 | 9,147 (22) | 8,911 (97) | 236 (3) | 1639 (18) | 1134 (12) | 6,374 (70) | ||||
| Ad26.COV2.S | 707 (2) | 677 (96) | 30 (4) | 707 (100) | ||||||
| ED or urgent care visit | ||||||||||
| All ED or urgent care visits | 21,522 (100) | 18,271 (85) | 3251 (15) | 0.09 | 11,812 (55) | 1920 (9) | 1269 (6) | 6,065 (28) | 456 (2) | 0.00 |
| First | 18,537 (86) | 15,822 (85) | 2715 (15) | 10,190 (55) | 1688 (9) | 1088 (6) | 5,181 (28) | 390 (2) | ||
| Repeat | 2,985 (14) | 2,449 (82) | 536 (18) | 1,622 (54) | 232 (8) | 181 (6) | 884 (30) | 66 (2) | ||
| Medical setting | 0.00 | 0.14 | ||||||||
| ED | 18,375 (85) | 15,598 (85) | 2777 (15) | 10,351 (56) | 1582 (9) | 1069 (6) | 5,000 (27) | 373 (2) | ||
| Urgent care clinic | 3,147 (15) | 2,673 (85) | 474 (15) | 1,461 (46) | 338 (11) | 200 (6) | 1,065 (34) | 83 (3) | ||
| Partner | 0.31 | 0.33 | ||||||||
| Intermountain Healthcare | 8,993 (42) | 7,600 (85) | 1393 (15) | 4,612 (51) | 908 (10) | 557 (6) | 2,700 (30) | 216 (2) | ||
| KPNW | 4,682 (22) | 4,277 (91) | 405 (9) | 2,100 (45) | 440 (9) | 327 (7) | 1,702 (36) | 113 (2) | ||
| Regenstrief Institute | 7,847 (36) | 6,394 (81) | 1453 (19) | 5,100 (65) | 572 (7) | 385 (5) | 1,663 (21) | 127 (2) | ||
| Age group | 0.35 | 0.41 | ||||||||
| 50–64 yr | 7,352 (34) | 5,819 (79) | 1533 (21) | 4,908 (67) | 547 (7) | 325 (4) | 1,336 (18) | 236 (3) | ||
| 65–74 yr | 6,569 (31) | 5,616 (85) | 953 (15) | 3,518 (54) | 611 (9) | 403 (6) | 1,915 (29) | 122 (2) | ||
| 75–84 yr | 5,235 (24) | 4,656 (89) | 579 (11) | 2,359 (45) | 539 (10) | 369 (7) | 1,893 (36) | 75 (1) | ||
| ≥85 yr | 2,366 (11) | 2,180 (92) | 186 (8) | 1,027 (43) | 223 (9) | 172 (7) | 921 (39) | 23 (1) | ||
| Covid-19 vaccine | 0.93 | NA | ||||||||
| Unvaccinated | 11,812 (55) | 8,965 (76) | 2847 (24) | 11,812 (100) | 0 | 0 | 0 | 0 | ||
| BNT162b2 | 5,212 (24) | 4,988 (96) | 224 (4) | 0 | 912 (17) | 711 (14) | 3,589 (69) | 0 | ||
| mRNA-1273 | 4,042 (19) | 3,891 (96) | 151 (4) | 0 | 1008 (25) | 558 (14) | 2,476 (61) | 0 | ||
| Ad26.COV2.S | 456 (2) | 427 (94) | 29 (6) | 0 | 0 | 0 | 0 | 456 (100) | ||
Percentages may not total 100 because of rounding. All patients with indeterminate immunization status (receipt of the first dose of mRNA-based vaccine 1 to 13 days before the index date for the medical visit) were excluded. ED denotes emergency department, ICU intensive care unit, and mRNA messenger RNA.
The standardized mean difference is the difference between the number of uninfected patients and the number of infected patients
Patients who were partially vaccinated with one dose of mRNA-based vaccine received the first dose at least 14 days before the index date and had not received the second dose by the index date. Patients who were partially vaccinated with two doses of mRNA-based vaccine received the second dose 1 to 13 days before the index date. Fully vaccinated patients received a single dose of the Ad26.COV2.S vaccine or both doses of mRNA-based vaccine (if the second dose of mRNA-based vaccine was received ≥14 days before the index date).
The standardized mean difference is the difference between the number of unvaccinated patients and the number of patients who received partial vaccination (first or second dose) or full vaccination.